Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBIT: 2014-2024

Historic EBIT for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$43.9 million.

  • Cartesian Therapeutics' EBIT fell 19.86% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.5 million, marking a year-over-year decrease of 71.03%. This contributed to the annual value of -$43.9 million for FY2024, which is 49.20% up from last year.
  • As of FY2024, Cartesian Therapeutics' EBIT stood at -$43.9 million, which was up 49.20% from -$86.4 million recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' EBIT peaked at $14.5 million during FY2022, and registered a low of -$86.4 million during FY2023.
  • Over the past 3 years, Cartesian Therapeutics' median EBIT value was -$43.9 million (recorded in 2024), while the average stood at -$38.6 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' EBIT spiked by 416.25% in 2022, and later slumped by 694.41% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' EBIT (Yearly) stood at -$56.8 million in 2020, then spiked by 91.91% to -$4.6 million in 2021, then spiked by 416.25% to $14.5 million in 2022, then crashed by 694.41% to -$86.4 million in 2023, then soared by 49.20% to -$43.9 million in 2024.